PsiOxus Therapeutics Ltd.
Harnessing the power of evolution to develop oncolytic viruses
This article was originally published in Start Up
Harnessing the power of Darwinian natural selection to find therapeutic oncolytic adenoviruses is one of the aims of the Oxford, UK-based start-up PsiOxus Therapeutics Ltd. Another is to develop the first therapies for the wasting syndromes cachexia and sarcopenia.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.